

SLC9A3R2 RABBIT PAB

货号: S219988

产品全名: SLC9A3R2 兔多抗

基因符号: SIPI; OCTS2; SIP-1; TKA-1; E3KARP; NHERF2; NHE3RF2; NHERF-2

UNIPROT ID: Q15599 (Gene Accession - NP_001123484.1)

背景: This gene encodes a member of the NHERF family of PDZ scaffolding proteins. These proteins mediate many cellular processes by binding to and regulating the membrane expression and protein-protein interactions of membrane receptors and transport proteins. The encoded protein plays a role in intestinal sodium absorption by regulating the activity of the sodium/hydrogen exchanger 3, and may also regulate the cystic fibrosis transmembrane regulator (CFTR) ion channel. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

抗原: Synthetic peptide of human SLC9A3R2

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 2000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Metabolism, Signal Transduction


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human renal cancer tissue using 219988 (SLC9A3R2 Antibody) at a dilution of 1/40 (Cytoplasm, Endomembrane system, Peripheral membrane protein).



In comparison with the IHC on the left, the same paraffin-embedded Human renal cancer tissue is first treated with the synthetic peptide and then with 219988 (Anti-SLC9A3R2 Antibody) at dilution 1/40.



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using 219988 (Anti-SLC9A3R2 Antibody) at a dilution of 1/40.



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with synthetic peptide and then with 219988 (Anti-SLC9A3R2 Antibody) at dilution 1/40.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
